Janus kinase (JAK) inhibitors represent a novel class of therapeutics that target and inhibit cytokine signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. This pathway plays a crucial role in regulating immune responses and cell growth. The efficacy of JAK inhibitors has been demonstrated in conditions such as psoriasis, psoriatic arthritis, and atopic dermatitis. Consequently, numerous researchers have explored the potential of JAK inhibitors in the treatment of other inflammatory skin diseases. Given the central role of the JAK/STAT pathway in cytokine release, JAK inhibitors are poised to become increasingly important in the management of inflammatory skin diseases in the future.